NASDAQ:QNCX 10 February 2026 - 18 May 2026

Quince Therapeutics Inc. shares headed into Monday’s session under fresh scrutiny after a late-Friday ownership filing added another data point to a stock already being driven less by drug-development news than by restructuring, Nasdaq compliance and cash runway.

Quince Therapeutics jumped roughly 48% to 78 cents in premarket action Wednesday, building on a steep rally that followed news the company brought in an adviser to weigh strategic alternatives.

Quince Therapeutics, Inc. dropped 6.6% to about $0.13 in premarket trading Tuesday. The biotech’s shares have been volatile lately, reacting to a string of company updates and regulatory decisions.